Novo Nordisk’s oral Wegovy (semaglutide) pill saw a rapid uptake in the U.S., with prescriptions reported to have increased roughly 500% in its second week on the market, analysts noted. The early demand spike follows the product’s recent launch and mirrors strong market interest in GLP‑1 therapies for weight management. Rapid uptake will put pressure on manufacturers, payers, and distribution channels to manage access and reimbursement. Observers will monitor whether this early momentum sustains into broader market adoption and how payers respond on coverage and prior‑authorization policies.